"The genetic variant we found lands right in this gene [for] the GLP-1 receptor, which happens to be the target for these medications." Humans typically have two copies of any given gene, but these copies can vary from each other
So, whats actually happening here
Study procedure (Koide et al., 2025) GLP-1RA therapy significantly reduced blood glucose levels, body weight, and body fat percentage Results showed that after 12 months of treatment, GLP-1RA therapy significantly reduced participants blood glucose levels (as measured by glycated hemoglobin), body weight, and body fat percentage
it tested whether that mechanism translates into weight and body-composition change [4]
Health and Human Services, who himself is advocating peptides, stem cells, and other interventions for which data are lacking
Researchers are measuring whether participants experience the progression of diabetic retinopathy